Former Olympic Champion Campbell-Brown Gets Provisional Drug Ban

Two-time Olympic 200-meter champion Veronica Campbell-Brown will fight to clear her name after accepting a provisional suspension from competition following a positive test for a banned substance.

Campbell-Brown, 31, was suspended while a disciplinary panel reviews her case, the Jamaican Athletics Administrative Association said yesterday in a statement. She tested positive for a banned diuretic on May 4 at the Jamaica International Invitational meet, the British Broadcasting Corp. reported.

Warren Blake, the association’s president, said Campbell-Brown had voluntarily withdrawn herself from competition. Her management company said the accusation that she had committed a doping offense came as a “shock to her” and she doesn’t accept “guilt of willfully taking a banned substance.”

“Veronica is not a cheat,” Claude Bryan, chief executive officer of Atlanta-based On Track Management Inc., said in a statement. “She has, via hard work and dedication, accomplished a record on the track which is absolutely remarkable. She will begin the process of clearing her name.”

Campbell-Brown won 200-meter and 400-meter relay gold medals at the 2004 Olympics in Athens and retained her 200-meter title in Beijing four years later. She’s won 16 medals at Olympic and World Championship meets, including a bronze in the 100-meters at last year’s London Games, where she also was a member of Jamaica’s silver medal-winning sprint relay team.

Before her positive test, Campbell-Brown had notified anti-doping officials that she had taken medication though hadn’t sought a so-called therapeutic use exemption that allows athletes to use certain banned substances to treat medical conditions, Jamaica’s Gleaner newspaper reported.

Diuretics are banned by the World Anti-Doping Agency for their ability to mask the presence of performance-enhancing drugs.

To contact the reporter on this story: Dan Baynes in Sydney at dbaynes@bloomberg.net

To contact the editor responsible for this story: Christopher Elser at celser@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.